NextCure, Inc. (NXTC)
NASDAQ: NXTC · Real-Time Price · USD
13.10
0.00 (0.00%)
Feb 13, 2026, 4:00 PM EST - Market open

NextCure Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
-----22.38
Revenue Growth (YoY)
-----252.58%
Cost of Revenue
-----46.55
Gross Profit
------24.18
Selling, General & Admin
13.2915.7219.7121.7120.5717.05
Research & Development
47.0341.4947.9354.250.19-
Operating Expenses
60.3157.2167.6475.9170.7717.05
Operating Income
-60.31-57.21-67.64-75.91-70.77-41.23
Interest Expense
-----0.08-0.18
Interest & Investment Income
2.34.094.911.171.44.74
EBT Excluding Unusual Items
-58.01-53.11-62.72-74.74-69.45-36.67
Merger & Restructuring Charges
-1.79-2.54----
Gain (Loss) on Sale of Investments
---0.010.060.07
Pretax Income
-58.01-55.65-62.72-74.73-69.39-36.6
Net Income
-58.01-55.65-62.72-74.73-69.39-36.6
Net Income to Common
-58.01-55.65-62.72-74.73-69.39-36.6
Shares Outstanding (Basic)
222222
Shares Outstanding (Diluted)
222222
Shares Change (YoY)
4.40%0.46%0.33%0.46%0.30%75.41%
EPS (Basic)
-23.87-23.88-27.04-32.32-30.15-15.95
EPS (Diluted)
-23.87-23.88-27.04-32.32-30.15-15.96
Free Cash Flow
-48.91-41.28-53.79-56-59.64-52.09
Free Cash Flow Per Share
-20.12-17.71-23.19-24.22-25.92-22.70
Gross Margin
------108.03%
Operating Margin
------184.22%
Profit Margin
------163.57%
Free Cash Flow Margin
------232.75%
EBITDA
-57.82-54.34-63.95-71.79-66.59-37.81
EBITDA Margin
------168.97%
D&A For EBITDA
2.492.873.684.124.183.41
EBIT
-60.31-57.21-67.64-75.91-70.77-41.23
EBIT Margin
------184.22%
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q